Abstract: A differential comparator that can sample 40-Gb/s signals and that operates off a single 1.2-V supply was designed and fabricated in 0.11-/spl mu/m standard CMOS technology. It consists of a ...

Despite randomised clinical trials (RCTs) being the gold standard for drug approval studies, the shift towards precision medicine has increased the use of single-arm trials (SATs). SATs lack results ...

Melatonin, the sleep aid tucked into many medicine cabinets, may also have a place in chronic pain care. A new analysis from ...

Suspect unfair appraisal in the private sector? Indian courts examine five key tests to detect bias. They first establish a ...

A US electronic health record study found that adults with obesity who started semaglutide or tirzepatide had lower recorded ...

Hemophilia A treatments were linked to different immune patterns in children in a small study of Hemlibra and factor VIII ...

The investment trust highlighted gains from stakes in global companies controlling 'pinch points' amid AI bottlenecks and ...

The SUBITO trial, presented by Rianne L Seefat and colleagues in The Lancet Oncology,1 revisits the long-standing debate ...

Recent autumns have proven that delaying drilling much beyond the end of October increases risk as weather shuts down ...

The deadline for the EU member states to implement the Pay Transparency Directive passed on 7 June 2026 - with only four of the 27 Member States ...

A forensic phonetician has explained his interpretation of a video that appeared to show a shooting defendant talking about a ...

Travere Therapeutics has transitioned into a rare disease commercial platform, driven by FILSPARI’s growth in IgAN and recent FSGS approval. More on TVTX stock.